Source comparison
Melanotan-1 Interactions: Drug Class Comparison
The table below compares major drug classes that interact with Melanotan-1, detailing their primary mechanism, effect on melanogenesis, phototoxicity risk, and recommendations for research protocol design. Tetracycline Antibiotics ROS generation upon UV exposu
This comparison does not assign a generated winner or score.
- The table below compares major drug classes that interact with Melanotan-1, detailing their primary mechanism, effect on melanogenesis, phototoxicity risk, and recommendations for research protocol design.
- Tetracycline Antibiotics
- ROS generation upon UV exposure, independent of MC1R pathway
- No direct effect on melanin synthesis; amplifies UV-induced oxidative stress
- High. Erythema and blistering at sub-MED UV doses
- Discontinue 7–10 days before Melanotan-1 initiation; if unavoidable, reduce UV exposure by 40–50%
- The combination creates multiplicative rather than additive phototoxicity. Avoid unless medically necessary and closely monitored
- Retinoids (Systemic/Topical)
- Stratum corneum thinning increases UV penetration to melanocyte layer
- Increases UV-induced melanin production but in context of higher baseline UV damage
- Moderate-High. Structural sensitization lowers MED threshold
- Pause topical retinoids 48 hours before UV exposure; systemic retinoids require washout period of 4–6 weeks
- Photoprotection from melanin is overwhelmed by structural UV penetration. Timing adjustments are insufficient with isotretinoin
- NSAIDs & Thiazide Diuretics
- Prostaglandin disruption (NSAIDs) or free radical generation (thiazides) during UV exposure
- No direct melanocortin pathway interference
- Moderate. Phototoxic reactions within 24–48 hours of UV exposure
- Schedule UV exposure >72 hours after NSAID dose; for chronic thiazide use, increase baseline MED testing
- Short-acting NSAIDs are manageable with timing; thiazides present chronic interaction requiring dose reduction or alternative diuretic
- Beta-Blockers
- Suppression of beta-adrenergic cAMP contribution to melanocyte signaling
- 15–25% reduction in melanin production from both UV and melanotropin stimulation
- None. No phototoxic mechanism
- Expect attenuated tanning response; may require 20–30% Melanotan-1 dose increase to achieve target melanin density
- Interaction is predictable and dose-adjustable. Less problematic than photosensitizers but requires recalibration
- Agouti Analogs / Skin-Lightening Compounds
- Direct MC1R antagonism. Competitive inhibition of melanocortin receptor binding
- Dose-dependent reduction in MC1R occupancy by Melanotan-1; blunts melanogenesis entirely at high antagonist doses
- None
- Discontinue all agouti-signaling compounds minimum 14 days before Melanotan-1 protocol; verify washout with baseline melanin measurement
- Direct receptor competition makes co-administration scientifically counterproductive. Protocols must be mutually exclusive
- Phosphodiesterase Inhibitors
- Inhibition of cAMP degradation extends melanocortin signaling duration
- Modest increase in melanin density but irregular spatial distribution (patchy hyperpigmentation risk)
- Avoid high-dose caffeine or prescription PDEIs during active Melanotan-1 dosing; if required, reduce peptide dose by 10–15%
- Prolonged cAMP doesn't improve uniformity. The interaction adds more risk (irregular pigmentation) than benefit